Evaluation effect of empaglifulazin on depression in patients with heart failure

Evaluation effect of empaglifulazin on depression in patients with heart failure with reduced ejection fraction: a randomizd clincal trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N41

Enrollment

Registered

2022-11-17

Start date

2022-11-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Systolic (congestive) heart failure

Interventions

Intervention 1: Intervention group: Patients will receive 25 mg of empagliflozin (Gloripa, Abidi Pharmaceutical Company) daily for three months in addition to the standard treatments for the treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Heart failure with reduced ejection fraction Aged 18 to 80 years Consented patients

Exclusion criteria

Exclusion criteria: History of using empagliflozin Kidney failure Symptomatic hypotension Systolic pressure below 100 or above 180 mm Hg Contraindications of empagliflozin Liver failure Pregnancy Lactation Malignancy

Design outcomes

Primary

Measure	Time frame
Hamilton score chek list. Timepoint: Before intervention and 1, and 3 months after intervention. Method of measurement: Hamilton depression checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTaher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 3335 5983

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026